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Abstract
Purpose To gain a greater understanding of the potential
of the Aurora kinase A inhibitor MLN8237 in the treatment
of pediatric malignancies.
Methods The activity of MLN8237 was evaluated against
28 neuroblastoma and Ewing sarcoma cell lines, and its in
vivo efﬁcacy was studied over a range of doses against 12
pediatric tumor xenograft models. Pharmacokinetic, phar-
macodynamic, and genomic studies were undertaken.
Results In vitro neuroblastoma cell lines were generally
more sensitive to MLN8237 than Ewing sarcoma lines.
MLN8237 demonstrated signiﬁcant activity in vivo against
solid tumor models at the maximum tolerated dose (MTD);
however, only 2 of 6 neuroblastoma models had objective
responses at 0.25MTD. In contrast, MLN8237 induced
objective responses at its MTD and at 0.5MTD in three
ALL models and in two out of three at 0.25MTD. Phar-
macokinetic studies at 0.5MTD demonstrated a Tmax of
0.5 h, Cmax of 24.8 lM, AUC(0–24) of 60.3 lM h, and 12 h
trough level of 1.2 lM. Mitotic indices increased 6–12 h
after MLN8237 administration. AURKA copy number
variation was frequent in xenografts, and expression was
highly correlated with copy number.
Conclusions Objective responses were more frequent in
tumors with decreased AURKA copy number (5/8) com-
pared to those with increased gene copy number (2/14).
This report conﬁrms the signiﬁcant activity against both
solid tumor and ALL xenografts at the MTD, with a steep
dose response. These data support clinical development of
MLN8237 in childhood cancer. Because of the steep dose–
response relationship, such studies should target achieving
trough levels of 1 lM or higher for sustained periods of
treatment.
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Introduction
One of the hallmarks of transformed/malignant cells is
their limitless proliferation capacity and defective cell
cycle checkpoints that, when functional, operate to detect
errors in replication processes and direct cells into apop-
tosis [1, 2]. Thus, interfering with mitosis has proven to be
a successful cancer treatment strategy [3]. Several com-
ponents of the mitotic machinery have been identiﬁed as
potential therapeutic targets, and antimitotic agents are
already crucial in the chemotherapy of both adult and
childhood malignancies. For instance, the microtubule-
targeting Vinca alkaloids are a central component of
curative regimens for many childhood solid tumors and
leukemias. Other appealing targets include mitotic kinesins
[3, 4], centromere components required for chromosome
alignment and spindle complex formation [5], as well as
Polo-like kinases and the Aurora kinases [6].
The Aurora serine/threonine protein kinases are a family
of three kinases (Aurora A, Aurora B, and Aurora C) with
different tissue and temporal expression proﬁles that play
key roles in mitosis and meiosis, defects in which can lead
to abnormal mitotic events and apoptosis induction [7]. The
essential nature of Aurora kinase A is highlighted by the
fact that genetically engineered null mice are embryonic
lethal (dying at the blastocyst stage) [8]. Aurora kinase A
activity is also required for centrosome duplication and
separation, microtubule–kinetochore attachment, spindle
checkpoint formation, cytokinesis [9, 10], the G2/M tran-
sition [11], and phosphorylation of Polo-like kinase 1 [12].
Further, Aurora kinase A has been implicated as an onco-
genic driver in human cancers [13]. Aurora kinase A has
been found to be overexpressed in cancer cells, and the
AURKA gene locus is ampliﬁed in selected adult tumors
[14]. However, limited information on the role of Aurora
kinase A in pediatric cancers is available.
Aurora kinase inhibitors are the focus of several phar-
maceutical development programs. Aurora kinase inhibi-
tors with different speciﬁcities and activities as well as
pharmacodynamic markers are currently being assessed,
and some are already well advanced in clinical trials
(reviewed in [15]). Most of these inhibitors show a broad
range of activity, with AZD-1152 being an example of a
selective Aurora kinase B inhibitor and MLN8054 (or its
derived compound, MLN8237, used in the present study)
an example of a selective Aurora kinase A inhibitor. The
effects of Aurora kinase A inhibition are multiple, as cor-
responds to the varied nature of its substrates, and include
abnormal spindle pole formation, proliferation reduction
(with G2-M arrest), and polyploidy [16], followed by
apoptosis induction. The latter could involve signaling
mediated by p53, as Aurora kinase A has been shown to
modify the phosphorylation status of p53 and histone H3
[17, 18] and to interact with the MYCN protein, limiting
p53 ubiquitination and degradation by the proteasome in
neuroblastoma cell lines [19, 20]. Although p53 is fre-
quently non-functional in cancer cells, inhibition of Aurora
kinase A by MLN8054 can lead to p73-dependent apop-
tosis in p53-deﬁcient cells [21]. Aurora kinase A has also
been reported to inﬂuence cell survival through the Akt
pathway and by interfering with IkBa [22].
The primary focus of the Pediatric Preclinical Testing
Program (PPTP) is to identify novel agents that have sig-
niﬁcant antitumor activity against models of childhood
solid tumors and acute lymphoblastic leukemia (ALL) as
one source of data to use in prioritizing clinical develop-
ment of such agents in the pediatric setting. The PPTP has
reported the single-agent evaluation of activity of the
Aurora kinase A inhibitor MLN8237 against its panels of
in vitro cell lines and in vivo xenograft models [23]. Both
the neuroblastoma and ALL panels were particularly sen-
sitive to the single-agent treatment. In fact, this Aurora
kinase A inhibitor is the only drug out of more than 20
tested with preferential activity against the neuroblastoma
panel. Despite these encouraging results, issues of how
responsiveness relates to drug exposure in mice and
humans, the dose range over which MLN8237 exerts sig-
niﬁcant antitumor activity, and the correlation of sensitivity
to Aurora kinase A expression remain unanswered. Here,
we report the in vitro activity of MLN8237 against an
extended panel of neuroblastoma and Ewing sarcoma cell
lines, and we report in vivo dose–response efﬁcacy studies
focusing on neuroblastoma and pediatric ALL xenografts,
as well as assessment of pharmacokinetic, pharmacody-
namic, and molecular parameters associated with these
responses.
Materials and methods
In vitro testing
In vitro testing was performed using DIMSCAN, a semi-
automatic ﬂuorescence-based digital image microscopy
system that quantiﬁes viable (using ﬂuorescein diacetate
[FDA]) cells in tissue culture multiwell plates [24]. Cells
were incubated in the presence of MLN8237 for 96 h at
concentrations from 1 nM to 10 lM and analyzed as pre-
viously described [25]. Two measures of sensitivity were
used; the absolute IC50, deﬁned as the drug concentration
inhibiting growth by 50% compared to controls, and the
relative IC50 (previously termed EC50), deﬁned as the drug
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effect.
Cell lines for in vitro testing
The cell lines used in this study were obtained from the
originator of the cell line or the Deutsche Sammlung
von Mikroorganismen unde Zellkulturen (Braunschweig,
Germany) or the American Type Culture Collection
(ATCC, VA, U.S.A.) and were maintained in culture
according to the corresponding initial report. All lines
underwent DNA genotyping as described [26]. Short tan-
dem repeat (STR) assay was used to verify each line
against the Children’s Oncology Group STR database (this
can be found in http://www.COGcell.org).
In vivo tumor growth inhibition studies
CB17SC scid
-/- female mice (Taconic Farms, German-
town NY) were used to propagate subcutaneously
implanted kidney/rhabdoid tumors, sarcomas (osteosar-
coma, rhabdomyosarcoma), and neuroblastoma tumors as
previously described [27–29]. Human leukemia cells were
propagated by intravenous inoculation in female non-obese
diabetic (NOD)/scid
-/- mice as described previously [30].
Details of these tumor panels can be obtained at http://
pptp.nchresearch.org/documents.html. Female mice were
used irrespective of the patient gender from which the
original tumor was derived. All mice were maintained
under barrier conditions, and experiments were conducted
using protocols and conditions approved by the institu-
tional animal care and use committee of the appropriate
consortium member. Ten mice (solid tumor models) and 8
mice (ALL models) were used in each control or treatment
group. Tumor volumes (cm
3) [solid tumor xenografts] or
percentages of human CD45-positive cells out of the total
leukocyte population in peripheral blood [hCD45, ALL
xenografts] were determined as previously described [31].
An event was deﬁned for the solid tumors as a quadrupling
of tumor volume from the tumor volume at start of treat-
ment, and for the ALL models when the proportion of
hCD45 reached 25%. Event-free survival (EFS) was esti-
mated for individual mice as the time required from
treatment initiation to reach the deﬁned event threshold.
Determination of response
Responses were assessed using three activity measures as
previously described [31]. For all the solid tumors on an
individual basis, progressive disease (PD) was deﬁned
as\50% regression from initial volume during the study
period and[25% increase in initial volume at the end of
study period. Stable disease (SD) was deﬁned as\50%
regression from initial volume during the study period
and B25% increase in initial volume at the end of the
study. Partial response (PR) was deﬁned as a tumor volume
regression C50% for at least one time point but with
measurable tumor (C0.10 cm
3). Complete response (CR)
was deﬁned as a disappearance of measurable tumor mass
(\0.10 cm
3) for at least one time point. A complete
response was considered maintained (MCR) if the tumor
volume was\0.10 cm
3 at the end of the study period.
Similarly, for the ALL xenografts, PD was deﬁned as a
continuous increase in hCD45 that reached event before the
end of the 42-day monitoring period, SD as hCD45 that did
not decrease to under 1% and did not reach the event
threshold, PR was deﬁned as a decrease in hCD45 to under
1% at only one time point, CR when the hCD45 stayed
under 1% for two consecutive measures, and MCR when
the hCD45 stayed under 1% for the last 3 weeks of the
monitoring period. Tumor growth delay (TGD) values
were calculated based on the numbers of days to event. For
each individual mouse that had PD and had an event in the
treatment groups, a TGD value was calculated by dividing
the time to event for that mouse by the median time to
event in the respective control group. Median times to
event were estimated based on the Kaplan–Meier event-
free survival distribution. For treatment groups only, if the
tumor response was PD, then the score was further clas-
siﬁed into PD1 or PD2 based on the TGD value: if the TGD
value B1.5, that mouse was considered PD1 while if the
TGD value[1.5, the mouse was considered PD2. Mice
that had PD but did not have an event at the end of the
study were coded as SD. A Median Group Response was
obtained for each cohort based on the median of the scores
of the individual mice. An in-depth description of the
analysis methods is included in the Supplemental Response
Deﬁnitions section. The three scores reﬂecting tumor
regression (PR, CR and MCR) were considered Objective
Responses (ORs).
Drug information and formulation
Millennium Pharmaceuticals, Inc., through the Cancer
Therapy Evaluation Program (NCI), provided MLN8237 to
the Pediatric Preclinical Testing Program. MLN8237 was
dissolved in DMSO and diluted in culture media for in
vitro tests or was suspended in 10% 2-hydroxypropyl-
b-cyclodextrin and 1% sodium bicarbonate in water and
administered to mice via oral gavage twice daily for 5 days
repeated each week for a total of 6 weeks for the solid
tumor xenografts, and for 3 weeks for the leukemia xeno-
grafts at doses of 20.8 mg/kg (the MTD), 10.4, 5.2, and
2.6 mg/kg.
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The exact log-rank test, as implemented using Proc
StatXact for SAS
, was used to compare event-free sur-
vival (EFS) distributions between treatment and control
groups. P values were two-sided and were not adjusted for
multiple comparisons given the exploratory nature of the
studies. The Mann–Whitney test was used to test for dif-
ferences in the median IC50 values for the Ewing sarcoma
and neuroblastoma cell lines.
Pharmacokinetic analysis
Blood was obtained by cardiac puncture 0, 0.5, 1, 2, 4, 6, 8,
12, and 24 h after dosing with MLN8237 (10 mg/kg) from
3 mice per time point. Plasma samples were prepared and
analyzed for MLN8237 concentrations by an LC/MS/MS
assay according to previously described methods for
MLN8054 [16].
Pharmacodynamic analysis
Accumulation of mitotic cells was used as a pharmacody-
namic measure of Aurora kinase A inhibition in NB-1771
tumor-bearing animals dosed with 20.8 mg/kg MLN8237.
Tumors were collected from animals at 0, 2, 6, 8, 12, and
24 h following MLN8237 dosing from 3 mice per time
point and were formalin-ﬁxed and parafﬁn-embedded.
Tumor sections (5 lm) were stained for two independent
mitotic markers, MPM2 (Mitotic protein monoclonal #2)
and histone H3 phosphorylated on serine 10 (pHistH3)
using the Discovery
 XT (Ventana Medical Systems, AZ,
U.S.A.) automated slide stainer. Sections were deparafﬁ-
nized with EZ prep
TM solution, and antigen retrieval was
completed with Cell Conditioning 1 solution, CC1 (Ven-
tana Medical Systems). The sections were incubated for
60 min at room temperature with mouse MPM-2 antibody
(1:100, Upstate Biotechnology, MA, U.S.A.) and rabbit
anti-phospho-histone H3 polyclonal (1:25, Upstate Bio-
technology). Biotin-conjugated anti-mouse antibody (Ani-
mal Research Kit, DAKO, CA, U.S.A.) was included to
amplify the MPM2 signal. Conjugated ﬂuorophores,
including Alexa Fluor 488-conjugated streptavidin (1:100,
Molecular Probes, OR, U.S.A.) or Rhodamine-Red-X-
AfﬁniPure goat anti-rabbit IgG (1:25, Jackson Immuno-
Research, PA, U.S.A.), were incubated for 60 min at room
temperature. Slides were washed in PBS and mounted with
DAPI Vectashield Hard Set Mounting Medium (Vector
Laboratories, CA, U.S.A.). Images were acquired using a
Canon E300 microscope (Canon, U.S.A.) with an auto-
mated stage. Five images from each slide were captured
using a 409 PlanFluor objective (Nikon Instruments,
U.S.A.) and analyzed on the MetaMorph
 image
processing software (Universal Imaging Corp., PA, U.S.A.)
that used a custom image processing application module.
Mitotic indices were determined as the percentage of total
cells that were positive for either pHisH3 or MPM2
staining.
Copy number analysis
Copy number analysis was performed using the Affymetrix
Genome-Wide SNP Array 6.0. DNA (500 ng) from each
sample was processed according to the manufacturer’s
instructions. SNP 6.0 data were processed from CEL ﬁles
to extract raw signal intensity values using dChip [32] PM-
only model-based expression analysis. The signal data
were then normalized using a reference-based normaliza-
tion algorithm [33]. For each marker in each array, the log2
ratio of tumor versus the median signal obtained from 90
reference samples from St. Jude Children’s Research
Hospital was calculated. Then, the segmentation algorithm
[34] implemented in the DNAcopy package from Biocon-
ductor [35] was applied to the above log2 ratio data to
identify copy number alterations for each tumor sample.
Copy number gains and losses were deﬁned by genomic
segments with log2 ratios[0.2 or\0.2, respectively.
Correlation analysis of gene expression and genomic
copy number variation
Gene expression data were obtained previously using the
Affymetrix HG-U133 Plus 2.0 array [36]. To estimate the
variance in gene expression attributed to underlying copy
number variation, a linear regression model was ﬁtted to
compare SNP data (segment log2 ratio) against expression
data (log2 signal). For each probe set on the HG-U133 Plus
2.0 array, the correlation coefﬁcient was calculated using
each segment falling within a genomic window of ±5k b
up/downstream of the annotated gene. Because multiple
segments and probe sets can arise within a given gene
boundary, the segment and probe set with the highest
correlation (R
2) value were selected for subsequent
analysis.
Results
MLN8237 is effective in vitro against both Ewing
sarcoma and neuroblastoma cell lines
In order to evaluate the activity of MLN8237 against cell
lines in vitro, an expanded panel of Ewing sarcoma
(n = 11) and neuroblastoma (n = 17) cell lines was tested
by DIMSCAN. The median relative IC50 for the Ewing
sarcoma and neuroblastoma extended panels of cell lines
1294 Cancer Chemother Pharmacol (2011) 68:1291–1304
123was 32 nM, while the median absolute IC50 was 37 nM
(Table 1). Corresponding ratios of the median relative and
absolute IC50 values to the comparable values for each cell
line tested are depicted in Table 1 and Supplemental Fig-
ure 1. The sensitivity of the Ewing sarcoma cell lines was
generally less than the median for both measurements
(ratio\1), whereas neuroblastoma cell lines were gener-
ally more sensitive to MLN8237 (ratio[1). Only one
Ewing sarcoma cell line, CHLA-56, was completely
resistant (IC50[10 lM) to MLN8237 exposure in vitro.
The relative IC50 values were signiﬁcantly lower for the
neuroblastoma panel (23 nM) than for the Ewing sarcoma
cell lines (58 nM, P = 0.0019), even after excluding the
resistant line (CHLA-56) from this analysis (P = 0.0039).
The cytotoxicity of MLN8237 (as assessed by minimum
T/C values (Ymin) approaching 0) was variable, with a
median Ymin value of 10.9%, and a range from 0.5 to 48%
(Table 1). The median Ymin values did not differ between
the Ewing cell lines (11.4%) and the neuroblastoma cell
lines (10.4%).
MLN8237 induces signiﬁcant cancer growth inhibition
in vivo with limited toxicity at its MTD
We previously reported MLN8237 as highly effective
against the PPTP’s neuroblastoma and ALL xenograft
models [23]. With the aim of conﬁrming these results, the
efﬁcacy of MLN8237 as a single agent at its MTD
(20.8 mg/kg administered twice daily) was evaluated in 9
solid tumor (6 of them neuroblastoma) and 3 ALL xeno-
graft models (Table 2). A complete summary of results is
provided in Supplemental Table I, including total numbers
Table 1 Summary of in vitro sensitivity of Ewing sarcoma and neuroblastoma cell lines
Cell line Histology Relative
IC50 (nM)
Absolute
IC50 (nM)
Median
EC50 ratio
Median
IC50 ratio
Ymin (%)
A-673 Ewing sarcoma 30 32 1.05 1.14 13.1
TC-32 Ewing sarcoma 34 39 0.92 0.94 6.5
TC-71 Ewing sarcoma 100 102 0.32 0.36 10.0
SK-N-MC Ewing sarcoma 66 72 0.48 0.51 2.8
CHLA-9 Ewing sarcoma 16 18 1.97 2.08 4.2
CHLA-10 Ewing sarcoma 56 60 0.57 0.60 4.7
CHLA-25 Ewing sarcoma 58 168 0.55 0.22 30.1
CHLA-32 Ewing sarcoma 92 136 0.35 0.27 13.1
CHLA-56 Ewing sarcoma 10,000 10,000 0.00 0.00 48.1
CHLA-258 Ewing sarcoma 82 132 0.39 0.28 18.8
COG-E-352 Ewing sarcoma 35 43 0.91 0.86 11.4
CHLA-90 Neuroblastoma 48 61 0.67 0.60 16.3
CHLA-119 Neuroblastoma 22 22 1.46 1.64 0.5
CHLA-122 Neuroblastoma 17 19 1.82 1.96 0.6
CHLA-136 Neuroblastoma 36 39 0.89 0.94 10.4
CHLA-140 Neuroblastoma 14 26 2.23 1.39 29.4
LA–N-6 Neuroblastoma 31 54 1.01 0.68 32.1
NB-1643 Neuroblastoma 32 37 0.98 0.99 10.2
NB-EBc1 Neuroblastoma 49 50 0.65 0.74 3.6
SK-N-BE(1) Neuroblastoma 24 28 1.35 1.32 4.0
SK-N-BE(2) Neuroblastoma 26 36 1.21 1.01 16.5
SMS-KAN Neuroblastoma 32 34 0.99 1.08 13.5
SMS-KANR Neuroblastoma 23 26 1.39 1.41 11.4
SMS-KCN Neuroblastoma 17 19 1.86 1.97 10.4
SMS-KCNR Neuroblastoma 9 10 3.42 3.65 6.6
SMS-LHN Neuroblastoma 20 32 1.61 1.13 25.1
SMS-MSN Neuroblastoma 17 22 1.92 1.66 16.1
SMS-SAN Neuroblastoma 18 20 1.79 1.80 5.9
Median 32 37 1.00 1.00 10.9
Minimum 9 10 0.00 0.00 0.5
Maximum 10,000 10,000 3.42 3.65 48.1
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123of mice, number of mice that died (or were otherwise
excluded), numbers of mice with events and average times
to event, tumor growth delay, as well as numbers of
responses and T/C values.
Toxicity was limited in the solid tumor study. Six of 180
mice died during the study (2.8%), 1 of 90 in the control
arms (1.1%), and 5 of 90 in the MLN8237 treatment arms
(5.6%). Toxicity was greater in the leukemia models (5 of
24 mice in the treated arm versus 1 of 25 controls), but
none of the groups met criteria setup for exclusion from
analysis ([25% mortality).
Antitumor effects were evaluated using the PPTP
activity measures for time to event (EFS T/C), tumor
growth delay (tumor volume T/C), and Median Group
Response and are summarized in Table 2. MLN8237
induced signiﬁcant differences in EFS distributions com-
pared to controls in all solid tumor models except SK-N-
AS, and in all three ALL models. Eight out of 11 evaluable
lines met the criteria for high activity with EFS T/C values
greater than 2 and with ﬁnal tumor volumes less than the
initial treatment volumes. The drug treatment at its MTD
resulted in 5 objective responses (partial or complete tumor
regressions) out of 9 models in the solid tumor panel and in
objective responses for all 3 of the ALL xenografts tested.
MLN8237 efﬁcacy against solid tumors shows a steep
dose–response in vivo
To investigate the efﬁcacy of MLN8237 over a range of
doses, we evaluated the efﬁcacy of the drug in vivo at the
MTD and 0.5, 0.25, and 0.125 of the MTD dose in six solid
tumors and 3 ALL models that demonstrated stable disease
or regression at the highest dose level. The in vivo testing
results for the objective response measure of activity are
presented in Supplemental Fig. 2 in a ‘heat-map’ format as
well as a ‘COMPARE’-like format, based on the scoring
criteria described in the ‘‘Material and methods’’ and the
Supplemental Response Deﬁnitions section. The latter
analysis demonstrates relative tumor sensitivities around
the midpoint score of 5 (SD). At the 0.5MTD dose
(10.4 mg/kg), only two of six solid tumor models demon-
strated objective responses (NB-1771, NB-1643), indicat-
ing a steep dose–response relationship for MLN8237
(Table 2). Dose–response relationships for KT-10, for
which antitumor activity was observed only at the highest
dose, and for NB-1643, for which MLN8237 exhibited
broad-range activity, are shown in Fig. 1 (panels a and b).
By contrast, for the ALL panel, MLN8237 induced CR in
each of three ALL models at 0.5MTD, and even at
0.25MTD, two out of three xenografts were classiﬁed as
objective responses (one CR, one PR; Fig. 1, panels c and
d), suggesting that the leukemia xenografts are more sen-
sitive to MLN8237 than the solid tumor models.
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123Pharmacokinetic and pharmacodynamic markers
Pharmacokinetic parameters for MLN8237 in mice were
assessed to evaluate whether the drug levels associated
with the high level of anticancer activity observed for the
xenograft models are attainable in the clinical setting. The
systemic exposure of MLN8237 was evaluated by dosing
non-tumored scid mice with a single dose of 10.4 or
20.8 mg/kg MLN8237 and collecting blood at various time
points to determine MLN8237 plasma concentrations. At
the 20.8 mg/kg dose, MLN8237 was rapidly absorbed with
a Tmax of 0.5 h and a corresponding Cmax of 42.5 lM. The
AUC0–24 h was 78.4 lM h, and the 12 h trough level was
1.8 lM. For the 10 mg/kg dose, the Cmax was 15.8 lM, and
the AUC0–24 h was 39 lM h (Fig. 2a).
Pharmacodynamic markers of MLN8237 on target
effects were investigated in mice bearing the NB-1771
tumor xenograft by assaying for a transient accumulation
of mitotic cells that occurs subsequent to Aurora kinase A
inhibition. The mitotic index was estimated in tumors
collected from mice that received a single 20.8 mg/kg dose
of MLN8237 by determining the percentage of cells posi-
tive for two distinct mitotic markers, MPM2 and pHistH3.
Representative photomicrographs of NB-1771 tumor
sections stained for MPM2 and H3 pHistH3 are shown in
Fig. 2b. The mitotic indices as evaluated through these two
markers increased (approximately twofold) within 6 h
following MLN8237 dosing, peaked at 12 h (three to
ﬁvefold increase), and returned to baseline levels 24 h after
dosing (Fig. 2c). There was concordance between both
pharmacodynamic markers, with very similar proﬁles of
mitotic indices obtained with each marker.
Molecular markers
Aurora kinases are overexpressed in Ewing sarcoma as a
consequence of the EWS-FLI1 gene fusion [37] while the
gene expression of Aurora kinase A in neuroblastoma is
not augmented [36]. mRNA expression levels of the Aur-
ora kinases were previously assessed using the Affymetrix
platform [36] and are shown in Fig. 3 (panel a) for the
xenografts tested in vivo (panel b) by the PPTP against
MLN8237 at its MTD as a single agent [23]. The ALL and
neuroblastoma xenograft panels showed relatively low
levels of expression of Aurora kinase A among all of the
xenograft tested. From the 60 samples tested for in vivo
sensitivity, 22 (37%) showed signiﬁcant copy number
variation at the Aurora kinase A locus (Figs. 3 panel c, 4).
Fig. 1 MLN8237 in vivo activity against individual solid tumor
xenografts (KT-10; NB-1643 xenograft panel a and b respectively) or
ALL xenografts (ALL-2; ALL-8, panel c and d respectively). Results
show growth of individual tumors in control, or mice treated with 2.6,
5.2, 10.4, or 20.8 mg/kg twice daily, 5-days per week for 6 weeks for
solid tumors or 3 weeks for ALL
1298 Cancer Chemother Pharmacol (2011) 68:1291–1304
123In many instances, copy number alteration at the Aurora
kinase A locus (AURKA) was attributed to large genomic
regions, even entire chromosomal arms, undergoing
ampliﬁcation or deletion on chromosome 20 (Supplemental
Fig. 3). Frequently, the gene dosage of Aurora kinase A
showed clear correlation with variation in expression
across the PPTP lines (Fig. 3). For example, copy loss in
the BT-28, D645, OS-1, and ALL-17 was associated with
substantially lower expression in those lines. The correla-
tion of gene expression variation with AURKA copy
number status was very strong (Pearson R = 0.573) for the
PPTP models. Indeed, this high positive correlation placed
the Aurora kinase A locus among the top 1.6% of all genes
tested, indicating that its gene expression is strongly
inﬂuenced by gene dosage. Copy number loss was noted in
8 models, and their response to therapy ranged from PD1
(insensitive, EW-5, BT-28) to CR or MCR (sensitive,
ALL-17, NB-1771, NB-1643, OS-1). Conversely, copy
gain was observed in approximately one half of the rhab-
domyosarcoma lines, suggesting that at least some of the
relatively high expression across the entire rhabdomyo-
sarcoma group may have arisen due to copy gain at the
Aurora kinase A locus. With the exception of Rh65
(MCR), which does not exhibit increased AURKA copy
number, the rhabdomyosarcomas were poorly sensitive to
MLN8237. Of the 14 tumors exhibiting copy number gain,
there were only 2 that had objective responses to
MLN8237 at the MTD.
Discussion
The main goal of the PPTP is to prioritize drugs being
developed predominantly for adult cancer treatment for
expedited clinical trials in children with relapsed/refractory
cancers. MLN8237, which has 200-fold speciﬁcity for
Aurora kinase A inhibition versus Aurora kinase B [16],
showed high-level activity at its MTD in its initial PPTP
evaluation; therefore, it was critical to validate and extend
these previous results. This was done by evaluating
MLN8237 against an extensive number of Ewing sarcoma
and neuroblastoma cancer lines in vitro, and by assessing
its activity in vivo against neuroblastoma and ALL xeno-
grafts across a range of doses with pharmacokinetic and
pharmacodynamic correlation.
Aurora kinase inhibitors have to date shown only
modest clinical activity against solid tumors in adults,
although more pronounced activity has been reported in
leukemia patients [14]. There are limited data available to
support Aurora kinase A as a relevant molecular target in
pediatric cancers besides the report by Shang et al. [38] and
the PPTP’s previous report of MLN8237 Stage 1 testing
[23]. In this latter publication, high levels of activity were
obtained against several solid tumor models and against
ALL xenografts of both T and B lineage. The most
intriguing set of results was that MLN8237 performed
more impressively than other investigational drugs, and
even established drugs, against the neuroblastoma panel as
a single agent at its MTD.
The Aurora kinases play critical roles in cell division,
and alteration of their expression and function has been
associated with oncogenesis. Knockdown of Aurora kinase
A using RNA interference results in mitotic spindle
defects, mitotic delay, and apoptosis in human cells [39],
while overexpression leads to transformation of normal
cells [40]. Also, Aurora kinase A is ampliﬁed or overex-
pressed in some adult cancers [41–43], which supports its
potential exploitation as a cancer therapeutic target [14].
Similarly, the overexpression of Aurora kinase A has been
postulated as predictive of susceptibility to inhibition of the
speciﬁc kinase activity. Thus, Ewing sarcomas, with
genetic alterations that enhance Aurora kinase A expres-
sion [37], should have higher sensitivity than the lower
expressing neuroblastoma or ALL panels. The results
presented in this study conﬁrm our previous results of high-
level activity for MLN8237 against neuroblastoma and
ALL xenografts, which express markedly lower Aurora
kinase A levels compared to other PPTP xenografts [23],
thereby calling into question the premise that overexpres-
sion of Aurora kinase A is associated with more effective
cell kill upon kinase inhibition. Although the Ewing sar-
coma xenografts had slightly increased expression of
AURKA compared to the median for all xenografts, our
study did not conﬁrm enhances in sensitivity to MLN8237
in vitro or in vivo. Indeed, the gene copy number analysis
for AURKA appears to support an inverse relationship
between Aurora kinase A expression and sensitivity.
Increased copy number was present in half of the rhabdo-
myosarcomas and in 14 of the solid tumors. Loss of copy
number was detected in 7 solid tumors and ALL-17. Fur-
ther, the correlation between gene expression variation and
copy number variation was strong, placing this locus in the
top 1.6% of all genes tested. Although there is no absolute
relationship between copy number variation and tumor
sensitivity, of the 14 solid tumors with increased copy
number, there were only two that showed sensitivity to
MLN8237 (1 PR, 1 SD). In contrast, of the eight models
demonstrating decreased copy number, there were ﬁve
sensitive models (3 MCR, 1 CR, and 1 SD).
The in vitro activity of MLN8237 against the Ewing
sarcoma and neuroblastoma extended panels (n = 11 and
n = 17, respectively) is consistent with the PPTP’s Stage 1
results for MLN8237, which showed median relative and
absolute IC50 values against all of the cell lines in the PPTP
in vitro panel of 49 and 61 nM, respectively [23]. The
larger number of Ewing and neuroblastoma cell lines
Cancer Chemother Pharmacol (2011) 68:1291–1304 1299
123described in this report compared to those studied in Stage
1 testing allowed detection of signiﬁcantly lower IC50
values for the neuroblastoma cell lines compared to the
Ewing sarcoma cell lines. Further, one Ewing sarcoma cell
line (CHLA-56) was resistant to MLN8237 (IC50[10
lM). The identiﬁcation of this highly resistant cell line
places it as a valuable tool for identifying resistance
mechanisms and warrants further investigation. Recently, a
functional Aurora kinase A mutation (T217D) that renders
the kinase impervious to MLN8054 and MLN8237 inhi-
bition has been reported [44] and points to a mechanism of
resistance independent from levels of expression.
Fig. 2 Pharmacokinetic and
pharmacodynamic activity of
MLN8237. a MLN8237
(10.4 mg/kg (ﬁlled circle)o r
20.8 mg/kg (open square)) was
dosed orally in non-tumored
scid mice, and blood was
isolated at various times
thereafter. MLN8237
concentrations were determined
in plasma from 3 different
animals per time point;
means ± standard error of the
means are shown;
b Representative
immunoﬂuorescence images of
tumor sections from NB-1771
xenografts stained with
antibodies against MPM2 and
pHistoH3 12 h after in vivo
administration of vehicle
control (upper panel)o r
MLN8237 (20.8 mg/kg, lower
panel); c The percentage of cells
positive for the mitotic markers
MPM2 (dark bars) or pHistH3
(white bars) were determined
from 3 different animals at
multiple time points;
means ± standard deviation are
shown. Mice bearing the human
neuroblastoma tumor NB-1771
were dosed once orally with
MLN8237 at 20.8 mg/kg
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123The efﬁcacy of MLN8237 treatment in vivo at its MTD
was conﬁrmed against the xenograft panel included in this
report. Out of 10 xenografts also evaluated in the previous
report, only one (OS-1) was scored more than one response
category apart from its previous score [23]. We have
conﬁrmed the high level of activity of MLN8237 against
xenograft models of neuroblastoma and ALL, when
administered as a single agent at its MTD. This further
demonstrates the potential relevance of Aurora kinase A
inhibition for neuroblastoma cancer treatment. However,
the efﬁcacy of MLN8237 (as indicated by the Median
Group Response) was reduced or lost for most of the solid
tumor models with dose reduction (Fig. 1). Thus, at
0.5MTD, only two xenografts exhibited an objective
Fig. 3 Gene expression, copy number analysis of the Aurora kinase
genes, and drug sensitivity of the PPTP in vivo models. a Relative
gene expression of Aurora kinases A, B, and C as determined by
Affymetrix gene expression arrays; b Tumor sensitivity to MLN8237
administered at the MTD (data from ref [23]) presented as a
categorical heat map. The colored heat map depicts group response
scores: MCR (red), CR (orange), PR (yellow), SD (gray), PD2 (light
green), PD1 (dark green), Not evaluated (black) (see Supplemental
Fig. 2, and Median Group Response scoring in the Supplemental
Response Deﬁnitions section); c Copy number assessment of Aurora
kinase A (AURKA) from the Affymetrix SNP 6.0 array. The upper
panel shows a continuous heat map representation of copy number
log2 ratio, while the lower panel shows a categorical representation of
copy gain (red), copy loss (blue), copy diploid (gray), or no data
(white) (color ﬁgure online)
Fig. 4 Copy number analysis
using the Affymetrix SNP 6.0
array. Copy number
representation of the in vivo
tested panel according to log2
ratio of segments identiﬁed
showing copy number status
across the Aurora kinase A
locus. The location of the
Aurora kinase A locus on
chromosome 20 is indicated by
a red bar across the top panel,
and green vertical lines indicate
the boundaries of the AURKA
locus (color ﬁgure online)
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123response, and at 0.25MTD, only one xenograft was clas-
siﬁed as PR. In contrast, the dose–response relationship for
the ALL xenografts was not as steep, with all three models
exhibiting objective responses at 0.5MTD and only one not
reaching an objective response upon further reduction to
0.25MTD.
Data for the pharmacokinetics of MLN8237 in patients
have recently been presented [45]. In patients receiving
50 mg BID, the Cmax and AUC0–24 h were 1.3 and
40 lM h, respectively. At the recommended phase 2 dose
of 50 mg BID for 7 days, average trough concentrations
exceeded 1 lM, the efﬁcacious concentration estimated in
previous preclinical work. In mice receiving MLN8237 at
10 mg/kg, the Cmax and AUC0–24 h were 16 and 39lMh ,
respectively, with the 12 h level being 1.2 lM. Thus,
results presented here suggest that drug exposures
achievable in patients may induce responses in only the
most sensitive of tumors and that dose intensity and
scheduling may be critical as a minority of the solid tumor
models exhibited objective responses at this level of drug
exposure.
When comparing the plasma exposure of MLN8237 to
the pharmacodynamic response, the peak of pharmacody-
namic activity (*8–12 h) was delayed relative to the peak
plasma exposure (0.5 h). This is consistent with previous
observations using the Aurora kinase A inhibitor
MLN8054 in a colon tumor xenograft [16] and is likely due
to the time it takes for a sufﬁcient number of cells to transit
the cell cycle and accumulate in mitosis subsequent to
Aurora kinase A inhibition as well as to the time during
which MLN8237 drug levels are above a threshold level
required for Aurora kinase A inhibition. The comparable
mitotic indices estimated using MPM2 and pHistH3 as
mitotic markers are consistent with speciﬁc inhibition of
Aurora kinase A by MLN8237 in vivo, as histone H3 is
phosphorylated by Aurora kinase B [46].
A likely critical step in the development of MLN8237
for use in the treatment of pediatric cancers is the devel-
opment of effective drug combinations. The limited
activity observed at reduced doses of MLN8237 as a single
agent against most solid tumor xenografts may be over-
come if synergistic interactions with other drugs can be
identiﬁed. Combinations of MLN8237 with established
drugs against in vivo models of pediatric solid tumors and
ALL are under evaluation by the PPTP.
The cumulative evidence of anti-tumor activity observed
in preclinical testing together with the results presented
here provides strong rationale for expeditious evaluation of
MLN8237 in the childhood cancer setting. A pediatric
phase 1/2 trial was opened in the Children’s Oncology
Group Phase 1 Consortium during 2008. As results from
that clinical trial emerge, it will be crucial to correlate
the observed anti-tumor activities with pharmacokinetic
measurements to assess whether drug levels are in the
range associated with substantial preclinical activity.
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